Market Overview - The S&P 500 reached a new record high, buoyed by investor confidence in corporate earnings growth and easing inflation for 2026, alongside the Federal Reserve's QE Lite injecting $40 billion into the market [1] - The VIX index remains low, indicating calm in equities, with no down month since April [1] - Precious metals, including gold, silver, and platinum, have hit record highs, driven by geopolitical concerns and expectations for interest rate cuts in 2026 [6][13] Corporate News - Sanofi agreed to acquire Dynavax Technologies for approximately $2.2 billion, aiming to expand its vaccine business [3][10] - Nike shares rose by 2.1% after Apple CEO Tim Cook purchased $2.95 million worth of Nike stock [1][5] - Intel shares fell by 3.2% following reports that Nvidia halted a test using Intel's technology [5][10] Economic Indicators - The latest MBA Mortgage Applications decreased by 5.0%, indicating a potential slowdown in the housing market [1] - Initial jobless claims are expected to be around 223,000, reflecting ongoing labor market conditions [29] Commodity Market - Gold prices reached $4,500 per ounce for the first time, while silver and platinum also surged to all-time highs, marking their best yearly gains since 1979 [6][8] - Copper prices hit a new record of approximately $12,200 per ton, set for its largest annual rise since 2009 [6][13]

Acquisition Details - Sanofi will acquire Dynavax Technologies for approximately $2.2 billion (1.9 billion euros), gaining access to an approved hepatitis B vaccine [1] - The acquisition price is set at $15.50 per share, representing a 39% premium over Dynavax's closing price of $11.13 [3] - Sanofi expects to finalize the acquisition in the first quarter of 2026 and will utilize available cash for the transaction [3] Strategic Context - This acquisition is part of Sanofi's strategy to diversify growth beyond its leading asthma drug Dupixent, following other significant acquisitions in 2023, including Vicebio for $1.5 billion and BluePrint Medicines for up to $9.5 billion [2] - The deal is aimed at expanding Sanofi's vaccine portfolio amid declining vaccination rates in the U.S. and recent policy changes affecting vaccine funding and recommendations [4][5] Market Implications - The acquisition will provide Sanofi with access to an experimental shingles vaccine currently in early-stage testing, which analysts believe could enhance the company's market position [6] - The shingles vaccine market is significant, with GSK's Shringix projected to achieve sales of 4 billion euros this year [6] Regulatory Challenges - Separately, Sanofi faced a setback as the U.S. FDA declined to approve its experimental drug tolebrutinib for multiple sclerosis, highlighting ongoing regulatory challenges for the company [7]

Last week, a panel handpicked by our vaccined denying Health and Human Services Secretary Robert F. Kennedy Jr. . reversed yet another long-standing recommendation on childhood vaccines.The CDC panel, which is stacked with antivaccine activists, voted to change the recommendation for when babies should get their first dose of the hepatitis B vaccine. Instead of a first dose within 24 hours of birth, which has been recommended for over 30 years, the panel now recommends delaying the first dose until the chil ...

Dark day today. The vaccine advisory committee handpicked by RF Kennedy Jr. . did exactly what everyone worried about when the antivaxer was first named health secretary.The panel voted to end the CDC's decadesl long recommendation of a vaccine, one that has been safely administered for more than 30 years and has caused, listen to this number, a 99% drop in cases of kids and teens catching a potentially fatal disease. It's the hepatitis B vaccine for newborns. It's something that's so successful, so uncontr ...

A CDC advisory panel voted to roll back a decadesl long recommendation on hepatitis B vaccines for newborns. >> Yeah, this is a big deal. I mean, the panel suggests that women who test negative for hepatitis B should decide with their doctor whether their baby should get a birth dose of this vaccine.>> The group also suggesting waiting until at least two months of age for that first dose if the vaccine is not given at birth. >> NBC News medical reporter Erica Edwards joins us now from outside the CDC with t ...

The hepatitis B vaccine has been administered to newborns for more than three decades. https://t.co/J7FNh0GZz9 ...

Your administration speaks a lot about gold standard science. What is gold standard science to you? >> It's science itself. Science means that you can question everything. >> You spoke about listening to the science. Today, the CDC's vaccine committee is considering changing the HEP schedule. And yet we have 30 years of experience that says that giving an newborn dose of HEP B dramatically reduces the cases of HEP B infants. It's practically been eliminated. Why? As a doctor, what do you think about that? W ...

Welcome back. Turning now to the CDC where a vaccine advisory panel handpicked by HHS Secretary RFK Jr. . is weighing whether to scrap the AY's long-standing recommendation that babies receive the hepatitis B vaccine within 24 hours of birth.That vote, which was planned for today, is now expected tomorrow, giving newborns the Hep B vaccine, has been credited with driving down infections in kids by 99% since it was implemented. But it has become the latest target of vaccine skeptics, including some on the CD ...

A group of CDC advisers is weighing some major policy changes to childhood vaccines. The panel is set to meet tomorrow and Friday to discuss whether to scrap the recommendation that newborns should receive hepatitis B vaccinations. >> Now, the vaccine has been credited with significantly preventing the spread of hepatitis B, but skeptics are questioning whether the benefits of the shot actually outweigh the potential health risks.NBC News medical reporter Dr. . Ashal joins us now. Dr. . Dr.. Sel, let's firs ...

Public Health Concerns - Delaying hepatitis B vaccine for newborns could increase childhood cases [1] - Increased childhood cases may ultimately lead to more deaths [1]